potassium voltage-gated channel subfamily C member 3Genealiases: KSHIIID · KV3.3 · SCA13
Q-omics provides the consensus-scored KCNC3 profile across patient tissues and cancer cell-line models. KCNC3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KCNC3 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, KCNC3 RNA expression shows 18,111 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, BLCA, and THYM as cancer lineages where KCNC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNC3 survival associations across molecular data types. KCNC3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNC3 RNA expression–survival associations across cancer types. High KCNC3 expression shows unfavorable associations in KIRP, COAD and LAML, but favorable associations in HNSC, CESC and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KCNC3 RNA expression.
This table summarizes KCNC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KCNC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNC3 shows lower tumor expression in KICH and higher tumor expression in BLCA, COAD, LIHC, HNSC and STAD. The BLCA box plot shows higher KCNC3 RNA expression in tumor versus normal tissue (log2 FC = +1.023, t-test p < 0.001).
This table shows molecular features associated with KCNC3 in patient tissues and cancer cell lines. In patient samples, KCNC3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
